Sugi Predict

Sugi Predict / Compounds / SCHEMBL1476527

SCHEMBL1476527

SCHEMBL1476527

NS(=O)(=O)c1ccc(N=C=S)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 11/20 1.00
▸ CA1 P00915 6/20 1.00
▸ MIF P14174 2/20 0.55
▸ CA9 Q16790 10/20 0.52
▸ CA12 O43570 6/20 0.52
▸ CA7 P43166 4/20 0.50
▸ PTGS2 P35354 3/20 0.50
▸ CA5A P35218 2/20 0.50
▸ CA5B Q9Y2D0 2/20 0.50
▸ PTGS1 P23219 2/20 0.50
▸ NOS3 P29474 1/20 0.48
▸ NOS1 P29475 1/20 0.48
▸ NOS2 P35228 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ P2RY6 Q15077 1/20 0.47
▸ USP2 O75604 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CA4 P22748 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483832 0.83 CA1 (0.70) CA2CA1MIFCA9ALDH1A1
SCHEMBL242025 0.81 CA2 (0.68) CA2CA1CA9CA12CA7
SCHEMBL1483567 0.79 CA1 (0.66) CA2CA1MIFCA9ALDH1A1
SCHEMBL31315339 0.79 CA1 (0.66) CA2CA1MIFCA9ALDH1A1
SCHEMBL2891113 0.79 CA1 (0.66) CA2CA1MIFCA9PTGS2
SCHEMBL6196292 0.79 CA1 (0.66) CA2CA1MIFCA9ALDH1A1
SCHEMBL8694424 0.79 CA1 (0.66) CA2CA1MIFCA9PTGS2
SCHEMBL668791 0.79 CA1 (0.66) CA2CA1MIFCA9ALDH1A1
Bitoscanate SCHEMBL8443297 0.78 CA1 (0.63) CA2CA1MIFCA9ALDH1A1
SCHEMBL1194107 0.78 CA1 (0.63) CA2CA1MIFCA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115411362-A Electrolyte for lithium ion battery, lithium ion battery and preparation method thereof 江苏海四达电源有限公司 2022-11-29 — — CN claimed
EP-4701635-A1 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS Universitat De Barcelona (ES) 2026-03-04 — — EP disclosed
US-20250257058-A1 COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO US GOV VETERANS AFFAIRS (US) 2025-08-14 — — US disclosed
EP-4508038-A1 COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO The United States Government as represented by the Department of Veterans Affairs (US) 2025-02-19 — — EP disclosed
WO-2024223907-A1 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS UNIVERSITAT DE BARCELONA (ES) 2024-10-31 — — WO disclosed
CN-116924987-A 4-piperazine thiourea benzene sulfonamide-1, 8-naphthalimide derivative and preparation method and application thereof 桂林医学院 2023-10-24 — — CN disclosed
WO-2023201374-A1 COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) 2023-10-19 — — WO disclosed
CN-115411362-A Electrolyte for lithium ion battery, lithium ion battery and preparation method thereof 江苏海四达电源有限公司 2022-11-29 — — CN disclosed
US-20220283175-A1 METALLOENZYMES FOR BIOMOLECULAR RECOGNITION OF N-TERMINAL MODIFIED PEPTIDES Encodia, Inc. (US) 2022-09-08 — — US disclosed
US-10730897-B2 Manganese chelate compounds GE HEALTHCARE AS (NO) 2020-08-04 — — US disclosed
EP-1042276-A1 THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY LLC (US) 2000-10-11 — — EP disclosed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 — — WO disclosed
WO-1999032433-A1 THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1999-07-01 — — WO disclosed
US-5914343-A TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, HOST VERSUS GRAFT REJECTION SUGEN, INC. (US) 1999-06-22 — — US disclosed
WO-1999021845-A2 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES AGOURON PHARMACEUTICALS, INC. (US) 1999-05-06 — — WO disclosed
US-5760066-A AIDS, ATHEROSCLEROSIS, CANCER SUGEN, INC. (US) 1998-06-02 — — US disclosed
WO-1996033179-A1 THIOAMIDES DERIVATES AND THEIR USE AS INHIBITORS OF HYPER-PROLIFERATIVE CELL GROWTH SUGEN, INC. (US) 1996-10-24 — — WO disclosed
EP-0424722-B1 Substituted (quinolin-2-yl-methoxy)phenyl-thioureas BAYER AG (DE) 1994-07-06 — — EP disclosed
US-5120744-A For combating diseases susceptible to the action of lipoxygenase inhibitors BAYER AKTIENGESELLSCHAFT (DE) 1992-06-09 — — US disclosed
EP-0424722-A2 Substituted (quinolin-2-yl-methoxy)phenyl-thioureas BAYER AG (DE) 1991-05-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257058-A1 COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO PELI1, MALT1, MCTS1 CA2 4361/4885CA1 2273/4885MIF 1658/4885
US-10730897-B2 Manganese chelate compounds MPI, SLC39A3, SLC39A14 CA2 349/4885CA1 920/4885MIF 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.